Match!
E. Le Rhun
French Institute of Health and Medical Research
37Publications
8H-index
219Citations
Publications 37
Newest
#1E. Le RhunH-Index: 8
#2Fabian Wolpert (UZH: University of Zurich)H-Index: 6
Last.L. MortierH-Index: 3
view all 8 authors...
Source
#1Solmaz Sahebjam (USF: University of South Florida)H-Index: 10
#2E. Le RhunH-Index: 8
Last.Pierfranco Conte (UNIPD: University of Padua)H-Index: 61
view all 9 authors...
Source
Source
#1E. Le RhunH-Index: 8
#2Patrick DevosH-Index: 33
Last.Michael WellerH-Index: 110
view all 15 authors...
Source
#1E. Le RhunH-Index: 8
#2Jennifer WalletH-Index: 4
Last.J. BonneterreH-Index: 5
view all 11 authors...
Source
#1Sara M. TolaneyH-Index: 29
#2Solmaz SahebjamH-Index: 10
Last.Carey K. AndersH-Index: 1
view all 8 authors...
Background Abemaciclib is a selective CDK4 & 6 inhibitor approved to treat patients (pts) with HR+, HER2- advanced breast cancer (ABC) on a continuous dosing schedule as monotherapy or in combination with endocrine therapy.1,2,3 Clinical data demonstrate that abemaciclib can penetrate the blood brain barrier resulting in comparable abemaciclib concentrations in brain metastases tissues, cerebrospinal fluid, and plasma.4 We report safety and efficacy results of abemaciclib in pts with leptomening...
Source
#1Joan SeoaneH-Index: 24
#2L. De Mattos-Arruda (Hebron University)H-Index: 7
Last.Michael Weller (UZH: University of Zurich)H-Index: 110
view all 5 authors...
4 CitationsSource
#1Ronan FlippotH-Index: 3
#2E AuclinH-Index: 1
Last.Benjamin Besse (Institut Gustave Roussy)H-Index: 43
view all 12 authors...
Source
#1E. Le RhunH-Index: 8
#2A MailliezH-Index: 6
Last.J. BonneterreH-Index: 5
view all 13 authors...
1 CitationsSource
#1Renata UrsuH-Index: 10
#2Laure ThomasH-Index: 6
Last.Antoine F. CarpentierH-Index: 37
view all 16 authors...
Source
1234